• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

#ASCO21: Gilead's Trodelvy reads out new subgroup data showing benefit in earlier-line...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 04, 2021 at 11:32: AM
via With AstraZeneca and Daiichi sniffing at its trail, Gilead has worked hard to hold an advantage for ADC Trodelvy in particularly hard-to-treat breast cancer patients. Now, the drugmaker is reading out more late-stage data showing some benefit in earlier-line patients, and it could help carve a path forward to a bigger market share.

article source
 




Top Bottom
Back
Quote